Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Chapman

Showing results (831-840 of 1,011) with videos related to

Pageof 102
Sort By:
Plos One|January 18, 2013
Urinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric studyAndreas D Kistler, Andreas L Serra, Justyna Siwy, et al.
Circulation. Cardiovascular Genetics|October 23, 2012
Hypertension susceptibility loci and blood pressure response to antihypertensives: results from the pharmacogenomic evaluation of antihypertensive responses studyYan Gong, Caitrin W McDonough, Zhiying Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2013
Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanomaFederica Catalanotti, David B Solit, Melissa P Pulitzer, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 4, 2016
Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trialMaría V Irazabal, Kaleab Z Abebe, Kyongtae Ty Bae, et al.
Melanoma Research|June 25, 2025
Programmed death ligand-1 PET imaging in patients with melanoma: a pilot studyNeeta Pandit-Taskar, Audrey Mauguen, Denise Frosina, et al.
The Journal of Neuropsychiatry and Clinical Neurosciences|August 10, 2023
Novel Oppositional Defiant Disorder or Conduct Disorder 24 Months After Traumatic Brain Injury in Children and AdolescentsDaniel S Lowet, Florin Vaida, John R Hesselink, et al.
The Journal of Neuropsychiatry and Clinical Neurosciences|August 22, 2022
Novel Psychiatric Disorder 6 Months After Traumatic Brain Injury in Children and AdolescentsJeffrey E Max, Imogen Drake, Florin Vaida, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 19, 2022
Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical TrialRonald T Gansevoort, Ali Hariri, Pascal Minini, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 30, 2010
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective mannerEric W Joseph, Christine A Pratilas, Poulikos I Poulikakos, et al.
The Journal of Neuropsychiatry and Clinical Neurosciences|November 20, 2013
Psychiatric disorders in children and adolescents six-to-twelve months after mild traumatic brain injuryJeffrey E Max, David Pardo, Gerri Hanten, et al.
Pageof 102

Showing results (831-840 of 1,011) with videos related to

Sort By:
Pageof 102
Plos One|January 18, 2013
Urinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric studyAndreas D Kistler, Andreas L Serra, Justyna Siwy, et al.
Circulation. Cardiovascular Genetics|October 23, 2012
Hypertension susceptibility loci and blood pressure response to antihypertensives: results from the pharmacogenomic evaluation of antihypertensive responses studyYan Gong, Caitrin W McDonough, Zhiying Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2013
Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanomaFederica Catalanotti, David B Solit, Melissa P Pulitzer, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 4, 2016
Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trialMaría V Irazabal, Kaleab Z Abebe, Kyongtae Ty Bae, et al.
Melanoma Research|June 25, 2025
Programmed death ligand-1 PET imaging in patients with melanoma: a pilot studyNeeta Pandit-Taskar, Audrey Mauguen, Denise Frosina, et al.
The Journal of Neuropsychiatry and Clinical Neurosciences|August 10, 2023
Novel Oppositional Defiant Disorder or Conduct Disorder 24 Months After Traumatic Brain Injury in Children and AdolescentsDaniel S Lowet, Florin Vaida, John R Hesselink, et al.
The Journal of Neuropsychiatry and Clinical Neurosciences|August 22, 2022
Novel Psychiatric Disorder 6 Months After Traumatic Brain Injury in Children and AdolescentsJeffrey E Max, Imogen Drake, Florin Vaida, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 19, 2022
Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical TrialRonald T Gansevoort, Ali Hariri, Pascal Minini, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 30, 2010
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective mannerEric W Joseph, Christine A Pratilas, Poulikos I Poulikakos, et al.
The Journal of Neuropsychiatry and Clinical Neurosciences|November 20, 2013
Psychiatric disorders in children and adolescents six-to-twelve months after mild traumatic brain injuryJeffrey E Max, David Pardo, Gerri Hanten, et al.
Pageof 102